Early Risk Assessment in TB contacts by new diagnostic tests (ERASE-TB)

Principal Investigators: Katherina Kranzer and Norbert Heinrich
Site Principal Investigator: Dr. Theodora Mbunda
Other Investigators: Dr. Nyanda Elias Ntinginya, Dr. Issa Sabi, Dr. Christina Manyama, Dr. Alfred Mfinanga, Dr. Harieth Mwambola
Research Centre: NIMR -MMRC, Mbeya Tanzania.
Study Duration: 2020-2024


Background / Purpose

The ERASE-TB study is being conducted to fill a critical unmet need for tuberculosis (TB) control. People who encounter an infectious TB case may become infected, and, among those who are do, most will stay healthy. However, some will go on to develop TB and such people would benefit from preventive treatment which would also inhibit the spread of the disease. 

Delayed diagnoses hampers tuberculosis (TB) control: globally, over four million TB cases remain undiagnosed each year. Bacterial burden and infectiousness are high, and lung damage is extensive in patients experiencing diagnostic delays.

The aim of this prospective multi-centre cohort study among household contacts (HHC), exposed to smear positive, infectious tuberculosis (TB) index cases is to evaluate new diagnostic tests and algorithms to diagnose TB before transmission occurs, earlier than current diagnostic approaches and to identify those most at risk for developing TB to allow targeted preventive treatment.

Clearly, earlier diagnosis is a prerequisite for successful TB control and ideally, individuals need to be diagnosed while TB is still incipient before becoming infectious. Preventive treatment of incipient TB could prevent long term morbidity, mortality, and onward transmission.

Approach

ERASE-TB will conduct a clinical cohort study among 2100 adolescent and adult household contacts (HHCs) exposed to smear positive, infectious TB in three HIV and TB high-burden Sub-Saharan African countries (Mozambique, Tanzania and Zimbabwe) to generate performance data on a number of new diagnostic assays, sampling strategies and testing algorithms to diagnose sub-clinical TB and accurately predict progression to disease with the aim of WHO endorsement and rapid in-country uptake and roll-out.

Funders

ERASE-TB is an EDCTP project funded by the European Commission under Grant Agreement no. RIA2018D32508.

ERASE-TB Partners:

  • Medical Centre of the University of Munich (LMU)
  • London School of Hygiene & Tropical Medicine (LSHTM)
  • Biomedical Research and Training Institute (BRTI) Zimbabwe 
  • National Institute for Medical Research (NIMR) Tanzania
  • Instituto Nacional de Saude (INS) Mozambique 
  • Dept. of Clinical Science & Education, Karolinska Institute 

Website: https://www.erase-tb.co.uk
Twitter: @EraseTb

 EDCTP EU nl

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya #Kaziinaendelea Wadau mbalimbali tunaoshirikiana katika miradi ya tafiti, wakiwemo watafiti kutoka LMU Klinikum wak… https://t.co/EbEXba9pik
NIMRMbeya RT @usembassytz: Wiki hii PEPFAR inapotimiza miaka 20 tunaangazia mafanikio ya programu hii. Je wajua kwamba hivi sasa @PEPFAR inawasaidia…
NIMRMbeya RT @usembassytz: Powerful editorial by Director of TACAIDS Dr. Leonard Maboko in The Guardian and @DailyNewsTZ about the impact of the @PEP
NIMRMbeya RT @usembassytz: PEPFAR, “imebadilisha mwelekeo wa VVU nchini Tanzania zaidi ya msaada mwingine wowote wa kigeni," amesema. Asante @Maboko_
NIMRMbeya RT @usembassytz: Makala nzuri kutoka kwa Mkurugenzi wa TACAIDS Dk. Leonard Maboko katika magazeti ya leo ya The Guardian na @DailyNewsTZ ku…
© 2017 NIMR - Mbeya Medical Research Center